Risk analysis of enfortumab vedotin: A real-world approach based on the FAERS database-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Risk analysis of enfortumab vedotin: A real-world approach based on the FAERS database

Published:2024-09 Issue:18 Volume:10 Page:e37544
ISSN:2405-8440
Container-title:Heliyon
language:en
Short-container-title:Heliyon

Author:

Zheng Fuchun,Du Yuanzhuo,Yuan Yuyang,Wang Zhipeng,Li Sheng,Xiong Situ,Zeng Jin,Tan Yifan,Liu Xiaoqiang,Xu Songhui,Fu Bin^ORCID,Liu Wei^ORCID

Publisher

Elsevier BV

Reference38 articles.

1. Cancer statistics, 2023;Siegel;CA A Cancer J. Clin.,2023

2. Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature;Mari;World J. Urol.,2018

3. Bladder cancer: a review;Lenis;JAMA,2020

4. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer;Roberts;Ann Oncol Off J Eur Soc Med Oncol,2006

5. Erdafitinib for the treatment of urothelial cancer;Marandino;Expert Rev. Anticancer Ther.,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP